Biology (Oct 2020)

Clinical Veterinary Boron Neutron Capture Therapy (BNCT) Studies in Dogs with Head and Neck Cancer: Bridging the Gap between Translational and Clinical Studies

  • Amanda E. Schwint,
  • Andrea Monti Hughes,
  • Marcela A. Garabalino,
  • Gustavo A. Santa Cruz,
  • Sara J. González,
  • Juan Longhino,
  • Lucas Provenzano,
  • Paulina Oña,
  • Monica Rao,
  • María de los Ángeles Cantarelli,
  • Andrea Leiras,
  • María Silvina Olivera,
  • Verónica A. Trivillin,
  • Paula Alessandrini,
  • Fabricio Brollo,
  • Esteban Boggio,
  • Hernan Costa,
  • Romina Ventimiglia,
  • Sergio Binia,
  • Emiliano C. C. Pozzi,
  • Susana I. Nievas,
  • Iara S. Santa Cruz

DOI
https://doi.org/10.3390/biology9100327
Journal volume & issue
Vol. 9, no. 10
p. 327

Abstract

Read online

Translational Boron Neutron Capture Therapy (BNCT) studies performed by our group and clinical BNCT studies worldwide have shown the therapeutic efficacy of BNCT for head and neck cancer. The present BNCT studies in veterinary patients with head and neck cancer were performed to optimize the therapeutic efficacy of BNCT, contribute towards exploring the role of BNCT in veterinary medicine, put in place technical aspects for an upcoming clinical trial of BNCT for head and neck cancer at the RA-6 Nuclear Reactor, and assess the feasibility of employing the existing B2 beam to treat large, deep-seated tumors. Five dogs with head and neck cancer with no other therapeutic option were treated with two applications of BNCT mediated by boronophenyl-alanine (BPA) separated by 3–5 weeks. Two to three portals per BNCT application were used to achieve a potentially therapeutic dose over the tumor without exceeding normal tissue tolerance. Clinical and Computed Tomography results evidenced partial tumor control in all cases, with slight-moderate mucositis, excellent life quality, and prolongation in the survival time estimated at recruitment. These exploratory studies show the potential value of BNCT in veterinary medicine and contribute towards initiating a clinical BNCT trial for head and neck cancer at the RA-6 clinical facility.

Keywords